Seattle Is the No. 1 Wired City in US

January 30, 2009

Seattle Is the No. 1 Wired City in US

According to Forbes, who conducts this and other types of research every year, Seattle has achieved the crown of being the most wired city in the United States in 2009, squeezing ahead and pushing Atlanta into second place. This is probably due to the septillion Starbucks WiFi hotspots, and it probably helps that Amazon.com and Microsoft are situated nearby. Why not check to see if your home town made it on the list of the top thirty? Glory lies in being a thoroughly networked city.
Read the rest of this entry »


Lozol vs Torsemide in LVH

January 24, 2009

Question:

Which dirutic potential in tratment of severe LVH I have severe concentric LVH and hypertensive male 51 years on enormin 100 Amlodipine 10 Lozol 1.5 Losartan 100

Recently my dr suggested Toresamide 20 in place of Lozol 1.5 Is toresamide as effective as Lozol 1.5 in regression of LVH This is for guidace only Thanx in advance

Answer:

Thank you for contacting NetWellness. The medication indapamide is a diuretic that is in a class of medication called thiazide diuretics. Indapamide works in the kidney to eliminate unneeded water and salt from the body. It is used for heart disease and hypertension.

Read the rest of this entry »


Over-the-counter diruetic

January 24, 2009

Question:

What is best and strongest over the counter diruetic.

Answer:

Thank you for visiting NetWellness. On this site, we try to answer general questions about medications but cannot diagnose or recommend treatment. You appear to have some very specific questions regarding over-the-counter diuretics, which can only be answered properly by a physician/pharmacist who is familiar with your current prescriptions, medical history, physical exam, and test results. Without this information it is not possible to safely recommend a product that is available over the counter whether it is a commercial or natural alternative. Take care.

Read the rest of this entry »


Weight gain with Lexipro

January 24, 2009

Question:

Do you gain weight with these kinds of medications? I`m aware of two individuals who have taken this drug for a long time, work out with a trainer, and still can`t lose weight. What is the real truth? Thank you

Answer:

Lexapro is the brand name for the drug escitalopram. It belongs to a class of antidepressant drugs called “selective serotonin reuptake inhibitors” or SSRIs. Weight gain as a side effect of escitalopram is negligible.

Read the rest of this entry »


Building a Mini-ITX Web Content Filter with Ubuntu

January 20, 2009

Building a Mini-ITX Web Content Filter with Ubuntu

Using an Mini-ITX motherboard and some spare parts lying around my study, I was able to put together an extremely powerful internet filtering appliance that is not only powerful but fast, reliable, and darn near impossible to circumvent by computer savvy teens. Most parents do not want to bother becoming the internet police of the household but today’s internet is a very hostile place with many different opportunities for trouble.
Read the rest of this entry »


KDE 4.2 RC1 Released

January 20, 2009

KDE 4.2 RC1 Released

The KDE project has released the first release candidate for KDE 4.2. “The KDE Community today announced the immediate availability of “Cilense”, (a.k.a. KDE 4.2 Release Candidate), the only planned release candidate for the KDE 4.2 desktop. Cilense is aimed at testers and reviewers. It should provide a solid ground to report last-minute bugs that need to be tackled before KDE 4.2.0 is released. Reviewers can use this release candidate to get a first look at the upcoming KDE 4.2 desktop which provides significant improvements all over the desktop and applications. It is not recommended for everyday use, however.” Read the rest of this entry »


5th Annual World Health Care Congress Europe, 13-14 May, Brussels, Belgium

January 20, 2009

A host of leading health care companies from Europe and the United States have joined the World Health Care Congress Europe, which will convene more than 600 health care leaders from more than 50 countries around Europe and the world for its 2009 event, 13-14 May, 2009 in Brussels, Belgium.

Leading companies include United HealthGroup International, Healthways, Humana, dbMotion, Aetna Global, Milliman, Premier, Map of Medicine, Marsh, Capsule Technologie and Catalyst Technologies.
Read the rest of this entry »


Risk-Reducing Salpingo-Oophorectomy For Women With BRCA Mutations: Value Confirmed By Meta-Analysis

January 20, 2009

Prophylactic salpingo-oophorectomy – removal of the ovaries and fallopian tubes – reduces the relative risk of breast cancer by approximately 50 percent and the risk of ovarian and fallopian tube cancer by approximately 80 percent in women who carry a mutation in the BRCA1 or BRCA2 gene, researchers report in the January 13 online issue of the Journal of the National Cancer Institute.

Previous studies have shown substantial reduction in the risks of breast and ovarian or fallopian tube cancers in BRCA1/2 mutation carriers following salpingo-oophorectomy. However, the magnitude of the benefit has been unclear.
Read the rest of this entry »


Pediatric Radiation Exposure And Effective Dose Reduction During Voiding Cystourethrography

January 20, 2009

UroToday.com – A study by Dr. Valerie L. Ward et al. compared radiation exposure and effective dose in children who underwent voiding cystourethrography (VCUG) performed with grid-controlled variable-rate pulsed fluoroscopy (GCPFL) to radiation exposure and effective dose in children who underwent VCUG performed with continuous fluoroscopy (CFL). These effective doses were compared with those estimated with radionuclide cystography (RNC).
Read the rest of this entry »


New Personalized Medicine Model Will Lead To Quicker Pharma Profits, Better Health Care And Lower Costs, Scientia Advisors Say

January 20, 2009

Despite predictions that pharma profits based on personalized medicine are still many years away, big pharmaceuctical companies could reap large, near-term revenues by pairing new diagnostic tools with existing, commercially available drugs.

So says Scientia Advisors, partner Amit Agarwal, who maintains that this new type of ” life cycle management ” for drugs could also improve patient care and reduce national health costs.

Read the rest of this entry »